Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

• US 6,191,102 B1
• Filed: 10/30/1997
• Issued: 02/20/2001
• Est. Priority Date: 11/05/1996
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: DiMarchi, Richard D., Efendic, Suad
• Primary Examiner(s): SAOUD, CHRISTINE J
• Application Number:
  US08/961,405
• Time in Patent Office: 1,209 Days
• Field of Search: 514/2, 530/300
• US Class Current: 514/4.8
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.

Claims

1. A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide analog (GLP-1 analog), a glucagon-like peptide derivative (GLP-1 derivative) or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

2. The method of claim 1, wherein the composition administered comprises GLP-1 (7-36) amide having the an amino acid sequence shown in SEQ ID NO:

5, or a pharmaceutically-acceptable salt thereof.

4. The method of claim 1, wherein the administering of the composition is by a peripheral parenteral route.

5. The method of claim 1, wherein the administering of the composition is intravenously.

6. The method of claim 1, wherein the administering of the composition is subcutaneously.

7. The method of claim 1, wherein the administering of the composition is continuous.

8. The method of claim 7, wherein the administering of the composition is at a rate of between 0.25 and 6 pmol/kg/min.

9. The method of claim 7 wherein the administering of the composition is at a rate of between 0.6 and 2.4 pmol/kg/min.

10. The method of claim 1, wherein the intravenous administration is intermittent.

3. A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising Val⁸-GLP-1(7-37)OH having the amino acid sequence shown in SEQ ID NO:

6, or a pharmaceutically-acceptable salt thereof, in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

11. A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising an agonist of glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

12. A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide analog (GLP-1 analog), a glucagon-like peptide derivative (GLP-1 derivative) or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

13. The method of claim 12, wherein the composition administered comprises GLP-1 (7-36) amide having the amino acid sequence shown in SEQ ID NO:

5, or a pharmaceutically-acceptable salt thereof.

15. The method of claim 12, wherein the administering of the composition is by a peripheral parenteral route.

16. The method of claim 12, wherein the administering of the composition is intravenously.

17. The method of claim 12, wherein the administering of the composition is subcutaneously.

18. The method of claim 12, wherein the administering of the composition is continuous.

19. The method of claim 12, wherein the intravenous administration is intermittent.

14. A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising Val⁸-GLP-1(7-37)OH having the amino acid sequence shown in SEQ ID NO:

6, or a pharmaceutically-acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

20. A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising an agonist of glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.